Immunogenic compositions comprising silicified virus and methods of use

Patent metadata

Field	Value
Publication number	US-9993543-B2
Application number	US-201414763947-A
Country	US
Kind code	B2
Filing date	Jan 31, 2014
Priority date	Jan 31, 2013
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as a T cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.

First claim

The invention claimed is:

1. A method of inducing a virus-specific immune response in a subject, comprising administering to the subject an effective amount of silicified virus or silicified virus particles, thereby inducing a virus-specific immune response in the subject.

2. The method of claim 1 , wherein the virus is vaccinia virus, a rotavirus, an adenovirus, an influenza virus, a lentivirus, a flavivirus, a hepatitis virus, a picornavirus, or a coronavirus.

3. The method of claim 2 , wherein the virus is a lentivirus and the lentivirus is an immunodeficiency virus.

4. The method of claim 3 , wherein the immunodeficiency virus is a human immunodeficiency virus.

5. The method of claim 2 , wherein the virus is a flavivirus and the flavivirus is West Nile virus, Japanese encephalitis virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or St. Louis encephalitis virus.

6. The method of claim 2 , wherein the virus is a hepatitis virus and the hepatitis virus is hepatitis A virus, hepatitis B virus or hepatitis C virus.

7. The method of claim 2 , wherein virus is a picornavirus and the picornavirus is poliovirus.

8. The method of claim 2 , wherein the virus is a coronavirus and the coronavirus is severe acute respiratory syndrome (SARS) virus or Middle East respiratory syndrome (MERS) coronavirus.

9. The method of claim 1 , wherein the virus-specific immune response comprises activation of virus-specific T cells, production of virus-specific antibodies, cytokine production, or any combination thereof.

10. The method of claim 1 , wherein administration is by a route selected from intramuscular, subcutaneous, oral and inhalation.

11. An immunogenic composition comprising (i) a silicified virus or silicified virus particles and (ii) a pharmaceutically acceptable carrier or an adjuvant, wherein the virus is vaccinia virus, a rotavirus, an adenovirus, an influenza virus, a lentivirus, a flavivirus, a hepatitis virus, a picornavirus or a coronavirus.

12. The immunogenic composition of claim 11 , wherein
the virus is a lentivirus and the lentivirus is an immunodeficiency virus;
the virus is a flavivirus and the flavivirus is West Nile virus, Japanese encephalitis virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or St. Louis encephalitis virus;
the virus is a hepatitis virus and the hepatitis virus is hepatitis A virus, hepatitis B virus or hepatitis C virus;
the virus is a picornavirus and the picornavirus is poliovirus; or
the virus is a coronavirus and the coronavirus is SARS virus or MERS virus.

13. The immunogenic composition of claim 12 , wherein the virus is a lentivirus and the lentivirus is a human immunodeficiency virus.

14. The immunogenic composition of claim 11 , wherein the adjuvant comprises a water-in-oil emulsion, incomplete Freund's adjuvant, alum, aluminum hydroxide, a toll-like receptor agonist, an immunostimulatory oligonucleotide or a biological adjuvant.

15. The immunogenic composition of claim 11 , wherein the pharmaceutically acceptable carrier comprises physiological saline, balanced salt solution, buffering agent, suspending agent, thickening agent, non-aqueous solvent, aqueous carrier, preservative, anti-oxidant, bacateriostat, or any combination thereof.

16. The immunogenic composition of claim 11 , contained in unit-dose form.

17. The immunogenic composition of claim 11 , wherein the silicified virus is silicified attenuated virus.

18. The immunogenic composition of claim 11 , wherein the virus particles are virus-like particles.

19. The method of claim 1 , wherein the silicified virus is silicified attenuated virus.

20. The method of claim 1 , wherein the virus particles are virus-like particles.

Assignees

• Univ Portland State
• Providence Health & Services—Oregon

Inventors

• Stedman Kenneth M
• Laidler James R
• Bahjat Keith

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C12N2795/14034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2740/16034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title